GEP20186916B - Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition - Google Patents

Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Info

Publication number
GEP20186916B
GEP20186916B GEAP201514216A GEAP2015014216A GEP20186916B GE P20186916 B GEP20186916 B GE P20186916B GE AP201514216 A GEAP201514216 A GE AP201514216A GE AP2015014216 A GEAP2015014216 A GE AP2015014216A GE P20186916 B GEP20186916 B GE P20186916B
Authority
GE
Georgia
Prior art keywords
pharmaceutical composition
castor oil
polyoxyethylene castor
acid compound
containing pharmaceutical
Prior art date
Application number
GEAP201514216A
Other languages
English (en)
Inventor
Pharmaceutical Co Ltd Santen
Original Assignee
Pharmaceutical Co Ltd Santen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Co Ltd Santen filed Critical Pharmaceutical Co Ltd Santen
Publication of GEP20186916B publication Critical patent/GEP20186916B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GEAP201514216A 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition GEP20186916B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10

Publications (1)

Publication Number Publication Date
GEP20186916B true GEP20186916B (en) 2018-11-12

Family

ID=53523959

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201514216A GEP20186916B (en) 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
GEAP201814216A GEAP201814216A (en) 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201814216A GEAP201814216A (en) 2014-01-10 2015-01-08 Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Country Status (19)

Country Link
US (3) US20160317512A1 (cg-RX-API-DMAC7.html)
EP (2) EP3093021B1 (cg-RX-API-DMAC7.html)
JP (5) JP6012775B2 (cg-RX-API-DMAC7.html)
KR (6) KR102111157B1 (cg-RX-API-DMAC7.html)
CN (2) CN110251516B (cg-RX-API-DMAC7.html)
AU (1) AU2015205268B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016015911B1 (cg-RX-API-DMAC7.html)
CA (1) CA2934612C (cg-RX-API-DMAC7.html)
EA (1) EA031723B1 (cg-RX-API-DMAC7.html)
ES (2) ES2953346T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20186916B (cg-RX-API-DMAC7.html)
IL (1) IL246654B (cg-RX-API-DMAC7.html)
MX (1) MX2016009058A (cg-RX-API-DMAC7.html)
MY (1) MY166210A (cg-RX-API-DMAC7.html)
PH (1) PH12016501327A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201605532YA (cg-RX-API-DMAC7.html)
TW (1) TWI612960B (cg-RX-API-DMAC7.html)
UA (1) UA121744C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015105134A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111157B1 (ko) * 2014-01-10 2020-05-14 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
KR101824829B1 (ko) 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제
TWI794140B (zh) 2015-07-09 2023-03-01 日商參天製藥股份有限公司 含有吡啶基胺基乙酸化合物之預防及/或治療劑
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
WO2018230713A1 (ja) 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
EP3689349A4 (en) * 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. MEDICINAL PRODUCT CONTAINING A COMPOUND OF PYRIDYLAMINOACETIC ACID
KR20200103041A (ko) 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
US11666563B2 (en) * 2017-12-28 2023-06-06 Santen Pharmaceutical Co., Ltd. Pharmaceutical preparation containing pyridyl aminoacetic acid compound
CN114761022B (zh) * 2019-11-29 2024-02-13 千寿制药株式会社 药物组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
CA2295512C (en) * 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
JP5460996B2 (ja) 2007-10-19 2014-04-02 大正製薬株式会社 眼科用剤
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
TW201309343A (zh) 2011-02-10 2013-03-01 參天製藥股份有限公司 經改善親水性藥物之藥物移行性之水性組成物
CN103596572A (zh) 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
TW201340960A (zh) 2012-02-27 2013-10-16 Rohto Pharma 眼科用組成物套組
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
CN104428911B (zh) 2012-07-09 2018-08-24 夏普株式会社 发光装置以及照明装置
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
KR102074020B1 (ko) 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
KR102111157B1 (ko) 2014-01-10 2020-05-14 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
MX385505B (es) 2014-01-10 2025-03-18 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico
KR101824829B1 (ko) * 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제
EP3689349A4 (en) 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. MEDICINAL PRODUCT CONTAINING A COMPOUND OF PYRIDYLAMINOACETIC ACID

Also Published As

Publication number Publication date
KR102458180B1 (ko) 2022-10-21
US20230372316A1 (en) 2023-11-23
KR102230683B1 (ko) 2021-03-19
EA201691139A1 (ru) 2017-02-28
JP2019034973A (ja) 2019-03-07
US20160317512A1 (en) 2016-11-03
EP3888654A1 (en) 2021-10-06
IL246654A0 (en) 2016-08-31
JP7546027B2 (ja) 2024-09-05
WO2015105134A1 (ja) 2015-07-16
JP2022189964A (ja) 2022-12-22
PH12016501327B1 (en) 2017-02-06
BR112016015911A2 (cg-RX-API-DMAC7.html) 2017-08-08
UA121744C2 (uk) 2020-07-27
JP2021011508A (ja) 2021-02-04
KR20160100977A (ko) 2016-08-24
EP3093021B1 (en) 2021-06-02
MX2016009058A (es) 2016-09-09
HK1224191A1 (zh) 2017-08-18
KR102675685B1 (ko) 2024-06-14
CN110251516A (zh) 2019-09-20
CA2934612A1 (en) 2015-07-16
CN105828817A (zh) 2016-08-03
BR112016015911B1 (pt) 2022-04-05
KR20180050770A (ko) 2018-05-15
JP2017031177A (ja) 2017-02-09
SG11201605532YA (en) 2016-08-30
EP3093021A1 (en) 2016-11-16
JP6449205B2 (ja) 2019-01-09
KR20210032547A (ko) 2021-03-24
KR20220146691A (ko) 2022-11-01
JP6012775B2 (ja) 2016-10-25
ES2953346T3 (es) 2023-11-10
IL246654B (en) 2020-05-31
JP7170020B2 (ja) 2022-11-11
JP6793172B2 (ja) 2020-12-02
KR101858373B1 (ko) 2018-05-15
KR102984133B1 (ko) 2026-06-29
TW201611833A (en) 2016-04-01
US20200113880A1 (en) 2020-04-16
JP2015147762A (ja) 2015-08-20
KR20240096869A (ko) 2024-06-26
KR102111157B1 (ko) 2020-05-14
US12678429B2 (en) 2026-07-14
EA031723B1 (ru) 2019-02-28
MY166210A (en) 2018-06-22
CN105828817B (zh) 2019-07-05
TWI612960B (zh) 2018-02-01
AU2015205268B2 (en) 2019-03-14
NZ721530A (en) 2021-03-26
CN110251516B (zh) 2022-05-03
EP3093021A4 (en) 2017-07-26
ES2874547T3 (es) 2021-11-05
EP3888654B1 (en) 2023-06-14
KR20200053651A (ko) 2020-05-18
AU2015205268A1 (en) 2016-07-14
GEAP201814216A (en) 2018-07-25
PH12016501327A1 (en) 2017-02-06
CA2934612C (en) 2021-09-07

Similar Documents

Publication Publication Date Title
GEAP201814216A (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EP4523705A3 (en) Glucagon derivative and a composition comprising a long acting conjugate of the same
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CR20200617A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
UA111542C2 (uk) Похідне складного ефіру 2-амінонікотинової кислоти та бактерицид, що містить зазначене похідне як активний інгредієнт
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
HK1219095A1 (zh) Vmat2的benzoquinolone抑制剂
PH12015500900B1 (en) A stabilized pemetrexed formulation
EP3207928A4 (en) Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
MY179951A (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
EP3067059A4 (en) Pharmaceutical composition for preventing or treating thyroid diseases, containing lonicera caerulea l. var. edulis fruit extract as active ingredient
WO2014153495A3 (en) Novel stat3 inhibitors
EP3225620A4 (en) Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition containing same
EP3103453A4 (en) Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
HK1224228A1 (zh) 新型制剂
HK1257171A1 (zh) 间变性淋巴瘤激酶(alk)和丝氨酸富集蛋白激酶 (sppk)的抑制剂及其使用方法
NZ627473A (en) Aryloxyacetamide compound and pesticide
EA201691741A1 (ru) Фармацевтическая композиция
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos